tiprankstipranks
Trending News
More News >
XRF Scientific Limited (AU:XRF)
ASX:XRF
Australian Market
Advertisement

XRF Scientific Limited (XRF) AI Stock Analysis

Compare
32 Followers

Top Page

AU:XRF

XRF Scientific Limited

(Sydney:XRF)

Select Model
Select Model
Select Model
Neutral 61 (OpenAI - 4o)
Rating:61Neutral
Price Target:
AU$2.00
▼(-5.66% Downside)
XRF Scientific Limited's overall stock score is primarily influenced by its strong financial performance, despite challenges in revenue growth and cash flow. The technical analysis indicates bearish momentum, which is a significant concern. The valuation suggests the stock is overvalued, but the dividend yield offers some compensation. The absence of earnings call and corporate events data means these factors do not impact the score.

XRF Scientific Limited (XRF) vs. iShares MSCI Australia ETF (EWA)

XRF Scientific Limited Business Overview & Revenue Model

Company DescriptionXRF Scientific Limited (XRF) is an Australian-based company that specializes in the development and manufacture of analytical instrumentation, particularly focusing on X-ray fluorescence (XRF) technology. Operating primarily in the sectors of mining, minerals, and materials analysis, XRF provides high-quality products and services designed for elemental analysis, including instruments for laboratory and on-site applications. The company also engages in the production of consumables and accessories that support its analytical instruments, catering to a diverse range of industries including geology, environmental testing, and quality control.
How the Company Makes MoneyXRF Scientific generates revenue through several key streams. Primarily, the company earns money from the sale of its XRF instruments, which are used for precise elemental analysis in various industries. This includes both the initial sale of the equipment and ongoing support services, such as maintenance and calibration. Additionally, XRF generates income from consumables, such as sample preparation materials and spare parts, which are essential for the operation of its instruments. The company also benefits from strategic partnerships with industry players and distributors, enhancing its market reach and sales capabilities. Furthermore, XRF may engage in research and development contracts or consultancy services, providing expert knowledge and tailored solutions that contribute to its revenue.

XRF Scientific Limited Financial Statement Overview

Summary
XRF Scientific Limited demonstrates strong financial performance with robust profitability margins and low leverage, indicative of operational efficiency and financial stability. However, the company needs to focus on sustaining revenue growth and improving cash flow dynamics to ensure long-term financial health.
Income Statement
75
Positive
XRF Scientific Limited has shown a strong revenue growth rate of 8.45% from 2023 to 2024, with significant gross profit and net profit margins at 43.88% and 14.85% respectively for 2024. The company also maintains a robust EBIT margin of 24.15% and an EBITDA margin of 25.61%, indicating solid operational efficiency. However, monitoring future revenue growth is crucial to maintain this trajectory.
Balance Sheet
80
Positive
The company exhibits financial stability with a low debt-to-equity ratio of 0.06, reflecting conservative leverage. A healthy return on equity (ROE) of 16.19% suggests effective use of shareholders' funds. An equity ratio of 80.43% underscores strong financial independence, minimizing risk of solvency issues. Nonetheless, maintaining such low leverage might limit growth potential.
Cash Flow
70
Positive
XRF Scientific Limited experienced a decrease in operating cash flow to net income ratio from 2023 to 2024, but maintains a positive free cash flow to net income ratio of 0.73, indicating sufficient cash generation. However, the free cash flow growth rate declined by 15.56%, warranting attention to reverse this trend for sustained liquidity and investment capacity.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue60.08M59.45M59.84M55.17M40.01M31.29M
Gross Profit27.43M28.79M26.27M22.00M16.46M12.89M
EBITDA15.97M15.63M15.32M13.22M9.44M8.05M
Net Income9.42M10.38M8.89M7.69M6.08M5.13M
Balance Sheet
Total Assets66.27M72.79M68.23M65.55M55.56M48.37M
Cash, Cash Equivalents and Short-Term Investments8.13M12.23M12.05M10.40M6.65M5.26M
Total Debt4.57M4.41M3.38M4.31M3.51M1.44M
Total Liabilities12.07M12.62M12.69M15.97M12.21M9.27M
Stockholders Equity54.21M60.17M54.89M49.25M43.48M39.10M
Cash Flow
Free Cash Flow9.37M8.39M6.45M7.63M2.63M3.86M
Operating Cash Flow10.37M10.14M8.09M8.42M3.15M4.51M
Investing Cash Flow-2.03M-2.21M-1.64M-782.43K-1.11M-652.62K
Financing Cash Flow-8.53M-7.75M-4.80M-3.88M-648.95K-2.24M

XRF Scientific Limited Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price2.12
Price Trends
50DMA
2.16
Negative
100DMA
2.00
Positive
200DMA
1.86
Positive
Market Momentum
MACD
-0.02
Positive
RSI
45.50
Neutral
STOCH
20.96
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:XRF, the sentiment is Neutral. The current price of 2.12 is below the 20-day moving average (MA) of 2.21, below the 50-day MA of 2.16, and above the 200-day MA of 1.86, indicating a neutral trend. The MACD of -0.02 indicates Positive momentum. The RSI at 45.50 is Neutral, neither overbought nor oversold. The STOCH value of 20.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:XRF.

XRF Scientific Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
61
Neutral
$10.43B7.12-0.05%2.87%2.86%-36.73%
61
Neutral
AU$303.14M28.6118.05%2.12%-1.09%14.88%
46
Neutral
AU$210.83M-43.66%46.74%-47.98%
36
Underperform
AU$1.47B-183.07%70.81%
36
Underperform
AU$274.65M-6.62%72.45%
32
Underperform
AU$671.33M-150.61%-186.15%
* Basic Materials Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:XRF
XRF Scientific Limited
2.12
0.50
30.86%
AU:MTM
Mt Monger Resources Ltd.
1.00
0.90
900.00%
AU:DTR
Dateline Resources Limited
0.37
0.36
3600.00%
AU:KAU
Kaiser Reef Ltd
0.31
0.10
47.62%
AU:GG8
Labyrinth Resources Limited
0.42
0.13
44.83%
AU:PTN
Kin Mining NL
0.08
<0.01
14.29%

XRF Scientific Limited Corporate Events

XRF Scientific Limited Announces Director’s Share Acquisition
Oct 23, 2025

XRF Scientific Limited announced a change in the director’s interest, specifically involving Vance Stazzonelli. The change involved an acquisition of 5,912 ordinary shares through an on-market trade, increasing his total holdings in the company. This adjustment in shareholding reflects ongoing investment and confidence in the company’s future prospects.

The most recent analyst rating on (AU:XRF) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on XRF Scientific Limited stock, see the AU:XRF Stock Forecast page.

XRF Scientific Limited Passes Key Resolutions at 2025 AGM
Oct 20, 2025

XRF Scientific Limited held its 2025 Annual General Meeting, where key resolutions were passed, including the approval of the remuneration report, the re-election of Director David Brown, and the issuance of performance rights to Mr. Vance Stazzonelli. These decisions are expected to strengthen the company’s governance and incentivize leadership, potentially enhancing its operational effectiveness and market competitiveness.

The most recent analyst rating on (AU:XRF) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on XRF Scientific Limited stock, see the AU:XRF Stock Forecast page.

XRF Scientific Showcases Advanced Sample Preparation Technology
Oct 20, 2025

XRF Scientific Limited presented its advanced technology in sample preparation and chemical analysis at its AGM in October 2025. The company’s focus on a wide range of minerals and materials positions it strongly in the mining and manufacturing sectors, enhancing its offerings to commercial labs and research institutions.

The most recent analyst rating on (AU:XRF) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on XRF Scientific Limited stock, see the AU:XRF Stock Forecast page.

XRF Scientific Reports Strong Q3 2025 Results with International Sales Boost
Oct 17, 2025

XRF Scientific Limited reported a positive performance for the September 2025 quarter, with a 16% increase in revenue and a 7% rise in profit before tax compared to the previous year. The company’s international sales were strong, particularly in Canada, Belgium, and Germany, and it saw significant growth in its Orbis crushers and precious metals products. The company anticipates continued growth in the December quarter, focusing on international sales, new product developments, and M&A opportunities.

The most recent analyst rating on (AU:XRF) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on XRF Scientific Limited stock, see the AU:XRF Stock Forecast page.

XRF Scientific Limited Announces Director’s Interest Change
Sep 30, 2025

XRF Scientific Limited announced a change in the director’s interest, specifically involving David William Kiggins. The change was due to the acquisition of 1,933 ordinary shares under a dividend reinvestment plan, increasing his indirect holdings through Glengarry Estate Pty Ltd. This adjustment reflects the company’s ongoing commitment to aligning leadership interests with shareholder value, potentially impacting stakeholder confidence positively.

The most recent analyst rating on (AU:XRF) stock is a Buy with a A$2.26 price target. To see the full list of analyst forecasts on XRF Scientific Limited stock, see the AU:XRF Stock Forecast page.

Director’s Share Acquisition Reflects Confidence in XRF Scientific
Sep 30, 2025

XRF Scientific Limited has announced a change in the director’s interest, with Frederick Sheppard Grimwade acquiring 11,822 ordinary shares through a dividend reinvestment plan, increasing his total holdings to 563,527 shares. This change reflects the director’s continued confidence in the company’s performance and strategic direction, potentially impacting investor perceptions and stakeholder confidence positively.

The most recent analyst rating on (AU:XRF) stock is a Buy with a A$2.26 price target. To see the full list of analyst forecasts on XRF Scientific Limited stock, see the AU:XRF Stock Forecast page.

XRF Scientific Limited Announces New Securities Quotation
Sep 26, 2025

XRF Scientific Limited has announced the issuance of 661,397 fully paid ordinary securities to be quoted on the Australian Securities Exchange (ASX) as of September 26, 2025. This move is part of a dividend or distribution plan, potentially impacting the company’s market presence and offering stakeholders an opportunity to engage with its financial growth.

The most recent analyst rating on (AU:XRF) stock is a Buy with a A$2.26 price target. To see the full list of analyst forecasts on XRF Scientific Limited stock, see the AU:XRF Stock Forecast page.

XRF Scientific Limited Announces 2025 AGM with Key Resolutions
Sep 15, 2025

XRF Scientific Limited has announced its Annual General Meeting (AGM) scheduled for October 20, 2025, at the Quest Hotel in Innaloo, WA. The meeting will address key resolutions, including the adoption of the Remuneration Report and the re-election of Mr. David Brown as a director. These resolutions are significant for the company’s governance and strategic direction, impacting shareholder engagement and the company’s leadership structure.

The most recent analyst rating on (AU:XRF) stock is a Buy with a A$2.26 price target. To see the full list of analyst forecasts on XRF Scientific Limited stock, see the AU:XRF Stock Forecast page.

XRF Scientific Director Diversifies Portfolio with Share Sale
Sep 8, 2025

XRF Scientific Limited announced a change in director David Brown’s shareholding, with Brown selling 1,000,000 shares for financial diversification purposes. Despite this sale, Brown has no immediate plans for further sales, and the transaction was executed through an on-market trade. This move reflects Brown’s strategy to diversify his investments, as a significant portion of his holdings are in XRF shares. The announcement, approved by the company’s board, highlights the director’s confidence in the company’s future performance, as he retains a substantial stake.

The most recent analyst rating on (AU:XRF) stock is a Buy with a A$2.26 price target. To see the full list of analyst forecasts on XRF Scientific Limited stock, see the AU:XRF Stock Forecast page.

XRF Scientific Limited Issues New Shares in Compliance with Corporations Act
Aug 25, 2025

XRF Scientific Limited has issued 385,294 fully paid ordinary shares without disclosure to investors under the Corporations Act 2001. This move complies with relevant legal provisions, and there is no additional information required for investors to assess the company’s financial position or the rights attached to the securities.

The most recent analyst rating on (AU:XRF) stock is a Buy with a A$2.26 price target. To see the full list of analyst forecasts on XRF Scientific Limited stock, see the AU:XRF Stock Forecast page.

XRF Scientific Limited Announces Quotation of New Securities
Aug 25, 2025

XRF Scientific Limited has announced the application for the quotation of 385,294 ordinary fully paid securities on the ASX, with an issue date of August 22, 2025. This move is part of previously announced transactions, potentially impacting the company’s market presence and offering stakeholders an opportunity to engage with its financial growth.

The most recent analyst rating on (AU:XRF) stock is a Buy with a A$2.26 price target. To see the full list of analyst forecasts on XRF Scientific Limited stock, see the AU:XRF Stock Forecast page.

XRF Scientific Limited Announces Proposed Securities Issue
Aug 22, 2025

XRF Scientific Limited has announced a proposed issue of 385,294 ordinary fully paid securities, with the issuance date set for August 22, 2025. This move is part of a placement or other type of issue, which could potentially impact the company’s market position by increasing its capital base and providing additional resources for its operations.

The most recent analyst rating on (AU:XRF) stock is a Buy with a A$2.26 price target. To see the full list of analyst forecasts on XRF Scientific Limited stock, see the AU:XRF Stock Forecast page.

XRF Scientific Completes Orbis Earnout Payment with Strong FY25 Performance
Aug 22, 2025

XRF Scientific Limited announced an update regarding the earnout payment for Orbis Mining Pty Ltd, highlighting Orbis’ strong financial performance in FY25 with a 20% revenue increase to $7 million and a 39% profit increase to $2.4 million. The earnout payment, amounting to $800,526, was settled through the issuance of 385,294 XRF shares, reflecting the company’s strategic decision to honor the former Orbis shareholders’ request to receive the earnout entirely in shares, thus reinforcing their commitment to XRF.

The most recent analyst rating on (AU:XRF) stock is a Buy with a A$2.26 price target. To see the full list of analyst forecasts on XRF Scientific Limited stock, see the AU:XRF Stock Forecast page.

XRF Scientific Announces Director’s Interest Change
Aug 22, 2025

XRF Scientific Limited announced a change in the director’s interest, specifically involving Vance Stazzonelli. The change includes the conversion of 384,088 performance rights into ordinary shares and the lapsing of 18,415 performance rights. This adjustment reflects the company’s ongoing management of executive incentives and could impact the company’s stock distribution and stakeholder interests.

The most recent analyst rating on (AU:XRF) stock is a Buy with a A$2.26 price target. To see the full list of analyst forecasts on XRF Scientific Limited stock, see the AU:XRF Stock Forecast page.

XRF Scientific Limited Announces Quotation of New Securities on ASX
Aug 22, 2025

XRF Scientific Limited has announced the application for the quotation of 1,409,597 fully paid ordinary securities on the Australian Securities Exchange (ASX), effective from August 21, 2025. This move is part of the company’s strategy to enhance its market presence and provide liquidity for stakeholders, potentially impacting its financial flexibility and shareholder value.

The most recent analyst rating on (AU:XRF) stock is a Buy with a A$2.26 price target. To see the full list of analyst forecasts on XRF Scientific Limited stock, see the AU:XRF Stock Forecast page.

XRF Scientific Limited Releases 2025 Corporate Governance Statement
Aug 19, 2025

XRF Scientific Limited has released its corporate governance statement for the financial year ending June 30, 2025, which is available on their website. The statement outlines the company’s adherence to the ASX Corporate Governance Council’s principles and recommendations, demonstrating its commitment to transparency and accountability in its operations. This announcement is significant as it reinforces the company’s dedication to maintaining high governance standards, which is crucial for its reputation and trust among stakeholders.

The most recent analyst rating on (AU:XRF) stock is a Buy with a A$2.22 price target. To see the full list of analyst forecasts on XRF Scientific Limited stock, see the AU:XRF Stock Forecast page.

XRF Scientific Limited: Advancing Sample Preparation and Analysis in Mining
Aug 19, 2025

XRF Scientific Limited’s latest investor presentation highlights their expertise in sample preparation technology and chemical analysis, catering to a wide range of minerals and materials. The company’s focus on advanced analysis techniques positions it as a key player in the mining and manufacturing sectors, potentially influencing market dynamics and stakeholder interests.

The most recent analyst rating on (AU:XRF) stock is a Buy with a A$2.22 price target. To see the full list of analyst forecasts on XRF Scientific Limited stock, see the AU:XRF Stock Forecast page.

XRF Scientific Limited Announces Dividend Distribution
Aug 19, 2025

XRF Scientific Limited has announced a dividend distribution of AUD 0.045 per share for its ordinary fully paid securities, with the record date set for September 12, 2025, and payment scheduled for September 26, 2025. This announcement reflects the company’s ongoing commitment to returning value to its shareholders and may positively impact its market positioning by reinforcing investor confidence.

The most recent analyst rating on (AU:XRF) stock is a Buy with a A$2.22 price target. To see the full list of analyst forecasts on XRF Scientific Limited stock, see the AU:XRF Stock Forecast page.

XRF Scientific Achieves Record Full-Year Financial Results
Aug 19, 2025

XRF Scientific Limited reported a record full-year result for June 2025, with revenue reaching $59.5 million and a net profit after tax of $10.4 million, marking a 17% increase from the previous year. The company’s growth was driven by strong activity in the mining industry and international sales, particularly in Asia, the Americas, and Europe. The Consumables division achieved a record profit before tax of $7.2 million, while the Precious Metals and Capital Equipment divisions also performed well. A final fully franked dividend of 4.5 cents per share was declared, reflecting a 15% increase from last year.

The most recent analyst rating on (AU:XRF) stock is a Buy with a A$2.22 price target. To see the full list of analyst forecasts on XRF Scientific Limited stock, see the AU:XRF Stock Forecast page.

XRF Scientific Limited Releases 2025 Annual Financial Report
Aug 19, 2025

XRF Scientific Limited has released its annual financial report for the year ending June 30, 2025. The report includes comprehensive financial statements and disclosures, reflecting the company’s financial performance and position over the past year. This release is crucial for stakeholders as it provides insights into the company’s financial health and strategic direction.

The most recent analyst rating on (AU:XRF) stock is a Buy with a A$2.22 price target. To see the full list of analyst forecasts on XRF Scientific Limited stock, see the AU:XRF Stock Forecast page.

XRF Scientific Limited Reports Increased Profits and Strategic Acquisition
Aug 19, 2025

XRF Scientific Limited reported a slight decline in revenue by 1% to $59.4 million for the year ending June 2025, while net profit after tax increased by 17% to $10.4 million. The company declared a final dividend of 4.5 cents per share, up from 3.9 cents the previous year. Additionally, XRF acquired Labfit Pty Ltd, contributing $536k in revenue and $91k in net profit before tax, enhancing its market position and operational capabilities.

The most recent analyst rating on (AU:XRF) stock is a Buy with a A$2.22 price target. To see the full list of analyst forecasts on XRF Scientific Limited stock, see the AU:XRF Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 23, 2025